http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2725601-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcee086ed3f150438e627cd7f4748416 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0676 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 |
| filingDate | 2007-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22fb8c76c74054d5eb138a1b791666ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b0359e05892b54e29ecd32ff36d7ea5 |
| publicationDate | 2019-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2725601-T3 |
| titleOfInvention | Differentiation of human embryonic stem cells |
| abstract | A method for differentiating human pluripotent stem cells into cells that express characteristic markers of the pancreatic endocrine lineage, comprising the steps of: a. Culture of human pluripotent stem cells in a tissue culture substrate coated with an extracellular matrix, wherein the extracellular matrix is selected from the group consisting of a solubilized basement membrane preparation extracted from mouse sarcoma cells, reduced solubilized basement membrane preparation by growth factor extracted from mouse sarcoma cells, laminin, fibronectin and human serum; b. Differentiation of human pluripotent stem cells into cells expressing characteristic markers of the definitive endodermal lineage, treating human pluripotent stem cells with 1 pg / ml at 100 μg / ml of activin A and 1 ng / ml at 1000 ng / ml of Wnt 3a in a first culture medium for 1 to 3 days, followed by culture of human pluripotent stem cells with 1 pg / ml of activin A and, optionally, 1 ng / ml at 1000 ng / ml of Wnt-3a in a second medium of culture for 1 day to 4 days; c. Differentiation of cells expressing characteristic markers of the definitive endodermal lineage in cells expressing characteristic markers of the pancreatic endodermal lineage, treating the cells expressing characteristic markers of the definitive endodermal lineage with 1 nM at 1 mM of retinoic acid and 50 pg / ml at 50 pg / ml of at least one fibroblast growth factor selected from the group consisting of FGF-2, FGF-4 and FGF-10 for 1 to 3 days; and d. Differentiation of cells expressing characteristic markers of the pancreatic endodermal lineage in cells expressing characteristic markers of the pancreatic endocrine lineage, treating cells expressing characteristic markers of the pancreatic endodermal lineage with 0.1 μM to 100 μM of L-685,458 for 3 to 5 days; wherein step b optionally further comprises treating the cells with 1 nM to 1000 nM of a GSK-3B inhibitor, and wherein the GSK-3B inhibitor is a GSK-3B XI inhibitor or a GSK inhibitor -3B IX. |
| priorityDate | 2006-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 193.